ADAG - Adagene Inc
NYSE * Health Care * Biotechnology
$1.96
+$0.04 (+2.08%)
About Adagene Inc
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
ADAG Key Statistics
Market Cap
$84.84M
P/B Ratio
2.44
EPS
$-0.64
Revenue Growth
-0.9%
Employees
138
How ADAG Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
#6
of 6
Size Rank
#6
of 6
Adagene Inc Company Information
- Headquarters
- China
- Website
- www.adagene.com
- Sector
- Health Care
- Industry
- Biotechnology